Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DME8ARP)

Drug Name

RX-3117 Drug Info

Synonyms

Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva

Indication

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Phase 2	[1]
Pancreatic cancer	2C10	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA [cytosine-5]-methyltransferase 1 (DNMT1)	TT6S2FE	DNMT1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
DNA [cytosine-5]-methyltransferase 1 (DNMT1)	DTT	DNMT1	6.508	6.687	6.296	6.565

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Bladder cancer

ICD Disease Classification

2C94

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
DNA [cytosine-5]-methyltransferase 1 (DNMT1)	DTT	DNMT1	0.00E+00	2.46	4.65

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02030067) Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies. U.S. National Institutes of Health.
3	Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.